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ABSTRACT
Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from
CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic
CDKN2A mutation or homozygous deletion is a very rare event, concerning less than 5% of patients.
Initial trials with palbociclib in serous ovarian cancer have shown very modest benefit in unselected
patient populations, thus underlining the need for a biomarker predicting response. We report the case
of a heavily pre-treated patient with a serous ovarian tumor harboring a homozygous deletion of the
CDKN2A gene that derived significant, prolonged clinical benefit from palbociclib, a CDK4/6 oral
inhibitor, with letrozole. Treatment with palbociclib and letrozole started on February 2018, with an
ongoing response after 12 months.
In conclusion, homozygous CDKN2A deletion is rare and could be used to predict response to CDK4/6
inhibitors in association with other genomic features. We encourage further trials in this direction.
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Ovarian cancer is the fourth most frequent cause of cancer
death for women in developed countries.1 Serous carcinomas,
90% of which are high grade, are the most common histolo-
gical type. Despite extensive use of chemotherapy, the prog-
nosis of recurrent disease remains unfavorable.1
CDK4/6 inhibitors are currently being investigated in ovar-
ian cancer and other tumor types,2,3 but their clinical efficacy
is modest in an unselected population and predicting which
patient will benefit is difficult. The combination of CDK4/6
inhibitors with fulvestrant or aromatase inhibitors was asso-
ciated with longer progression-free survival4 and overall
survival5 in hormone receptor-positive breast cancer but the
identification of predictive biomarkers is still lacking.
Here we report the case of a patient with platinum-
refractory, high grade serous ovarian cancer with bi-allelic
CDKN2A loss, intact RB1 and without CCNE1 amplification
who had a durable response to the association of palbociclib
and letrozole.
Case presentation
The patient was diagnosed in 2011 with high-grade serous ovar-
ian cancer (HGSC) stage IIIC and has been managed in our
institution since then. She was 49 years old at diagnosis, and her
family history was not informative. Germline BRCA1/BRCA2
testing did not reveal a pathogenic variant.
The patient initially presented with ascites and a radiological
image of “omental cake”. She received chemotherapy with
carboplatin AUC 5 and paclitaxel 175 mg/m2, without clinical
or radiological response. She then received a second line of
chemotherapy with gemcitabine 1000 mg/m2 for ten cycles,
resulting in radiologically stable disease, a decrease of ascites
and of CA-125 concentration. Radiological progression was
observed 6 weeks after the last treatment cycle, justifying the
introduction of third-line chemotherapy with liposomal doxor-
ubicin 20 mg/m2 for 4 cycles, without clinical benefit. The
fourth-line chemotherapy with weekly intravenous topotecan
4 mg/m2 resulted in a good clinical and radiological response
after 4 cycles. We observed the complete regression of ascites,
reduction of an ovarian mass, and the decline of CA-125 from
314 to 36 kU/L. This allowed the patient to undergo debulking
surgery in May 2013, which was unfortunately incomplete and
left a 2 cm residual tumor. The histological review of the surgical
specimen showed a morphological and immunohistochemical
pattern of high-grade serous ovarian cancer (Figure 1), consis-
tent with the initial diagnosis. After three additional cycles of
weekly topotecan, the patient attained a complete clinical and
biological remission, which lasted until June 2014. At this
moment, the appearance of localized symptomatic ascites led
the medical team to perform paracentesis, which cytologically
confirmed the recurrence. Given the excellent response to
weekly topotecan, the patient was again treated with the same
regimen from June 2014 to February 2015, and once more in
October 2015 (4 cycles), with good clinical response and
a decrease of ascites.
In June 2017, the patient received topotecan for the fourth
time but the disease progressed during treatment with the
appearance of ileus, requiring the placement of a nasogastric
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tube. Surgery could not be performed because of extensive
peritoneal carcinomatosis. The patient was hospitalized for
2 months and received parenteral nutrition, with minimal
oral intake. She received seven cycles of weekly paclitaxel
80 mg/m2. Bevacizumab was omitted because of therapeutic
anticoagulation for deep vein thrombosis and the risk of
intestinal perforation in the context of sub-ileus.
A computed tomography (CT)-scan in January 2018 showed
stable disease (Figure 2a), and the CA-125 concentration
remained stable around 90 kU/L (Figure 3).
Molecular tumor testing by next-generation sequencing of 50
genes and copy number variation analysis performed previously
Figure 1. Histological and immunohistochemical images of the tumor, consistent with high grade papillary serous carcinoma. The tumor showed a typical
morphology with numerous papillary formations and psammoma bodies. The tumor cells are atypical with irregular nuclei and macro-nucleoli (A). They stain
positive for the estrogen (B) and progesterone receptors (C) and for PAX8 (D) .
Figure 2. CT-scans in January 2018 (A) in October 2018 (B) and in February 2019 (C), showing a tumor reduction (reaching criteria for partial response according to
RECIST) and the resolution of the pathological intestinal dilation (white arrows) .
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had shown a bi-allelic focal deletion of CDKN2A (Figure 4a),
which was also confirmed by the absence of p16 expression in
immunohistochemistry (Figure 4b). We did not find any other
pathogenic mutation nor other targetable focal copy number
alterations. Specifically, there was no amplification in CCND1,
CCNE1 and no loss in RB1. We did find a modest diffuse copy
number gain in 7p14 (three copies ofCDK6), 12q13 (three copies
of CCND2) and 12q13 (three copies of CDK4). The tumor also
expressed estrogen receptors (ER, 80%) and progesterone recep-
tors (PgR, 30%) by immunohistochemistry.
Figure 3. Evolution of CA-125 concentration (kU/L) after introduction of palbociclib and letrozole (arrow) .
Figure 4. (A) Genomic profile generated by SNP array showing the total loss of CDKN2A. (B) Representative P16INK4a immunohistochemistry image showing the loss
of its expression in cancer cells. Inset corresponds to a zoomed portion of the image.
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The patient maintained a good performance status (ECOG 1)
despite the need for parenteral nutrition support. Therefore, we
proposed a combination of palbociclib (125mg daily for 3 weeks,
then a week off) and letrozole (2.5mg daily). This treatment
produced significant clinical benefit, including the recovery of
a normal intestinal transit, allowing the progressive introduction
of exclusive oral nutrition. A first CT-scan in April 2018 showed
the resolution of pathological intestinal dilation and a slight
tumor reduction which did not meet the RECIST criteria for
a partial response. A follow-up CT in October 2018 showed an
ongoing response (Figure 2b) and the latest CT scan in
February 2019 showed a further decrease of 46% from baseline
in two measurable lesions, corresponding to a partial response
(Figure 2c). The treatment was well-tolerated, without nausea or
mucositis. Transient G3 neutropenia occurred twice, after cycles
7 and 10, and resolved with a one-week treatment pause.
Discussion
Activated CDK4 and CDK6 phosphorylate the Rb protein
(RB1 gene), releasing the E2F transcription factors which
mediate cell cycle progression. The Cyclin D-CDK4/6 com-
plex is inhibited by p16 (CDKN2A gene) in response to DNA
damage or other stressors. CDKN2A is often mutated or lost
in head and neck cancer, pancreatic cancer and melanoma,
resulting in inappropriate CDK4/6 activation and excessive
proliferation.6 The loss of function by epigenetic mechanisms
is far more frequent in several other cancer types.7 This lends
theoretical support to the use of CDK4/6 inhibitors although
their efficacy depends on an intact downstream Rb protein.7,8
The use of cyclin-dependent kinases 4 and 6 inhibitors,
such as palbociclib, is being investigated in ovarian cancer
after in vitro studies demonstrated growth inhibition in cells
with p16 loss.9 Little evidence exists regarding the clinical
benefit of CDK4/6 inhibitors in ovarian cancer. One phase
I study in a Japanese population reported a clinical benefit of
palbociclib 100 mg once daily in an ovarian cancer patient,
with stable disease and a progression-free survival (PFS) of
4 months.10 One prospective phase II study of 40 molecularly
unselected patients with high-grade ovarian cancer demon-
strated good tolerance of the CDK4/6 inhibitor as a single
agent, with a modest median PFS of 3.7 months, correspond-
ing to 30% at 6 months.2 Only one patient attained an objec-
tive radiological response (1 of 26 evaluable). An additional
three patients attained a response using the GCIG CA125
criteria (4/30 evaluable). Despite an undeniable signal of effi-
cacy for very few patients, the use of palbociclib cannot be
recommended for unselected ovarian cancer patients.
Reliable predictive biomarkers are needed, but predicting
response to palbociclib is difficult. Several genomic alterations
are thought to result in excessive CDK4/6 activity and should
render tumors sensitive to CDK4/6 inhibitors,11 but this was not
reflected in the biomarker assessment of clinical trials.12–14 For
example, in the phase II PALOMA-1 trial, the combination of
palbociclib and letrozole was equally efficacious in tumors with
CCND1 amplification or CDKN2A loss, and in tumors without
these features.12 Additional complications arise from the use of
different techniques for biomarker assessment, for example,
gene expression, immunohistochemistry, and DNA sequencing.
Predicting resistance to CDK4/6 inhibitors appears to be some-
what clearer, since downstream events, such as loss of RB1 or
amplification of CCNE1 bypass the drug’s mechanism of func-
tion and have emerged as resistance mechanisms in multiple
studies.15–17
Interestingly, even though the alterations affecting the Rb
pathway can be found in the majority of ovarian cancers (up
to 67%), the bi-allelic deletion of CDKN2A that we saw in this
patient is a rare event (2%).18 Furthermore, the bi-allelic
deletion of CDKN2A was focal, limited to a narrow region
of 1728 kb, and therefore a plausible driver event. In addition,
our patient did not have CCNE1 amplification, which is found
in more than 20% of patients, or RB1 loss (2% of patients).
Both of these alterations would be likely to induce resistance
to palbociclib. The copy number gains of CDK4, CDK6, and
CCND2 were diffuse and resulted only in a single additional
gene copy, a presentation that would be consistent with
a passenger alteration and should not reduce the tumor’s
reliance on CDK4/6 activation. Overall, the constellation of
molecular findings reported in our patient is rare and consis-
tent with an expectation of benefit from palbociclib.
Noteworthy, we did not find any hotspot mutation of TP53,
which is known to be mutated in over 90% of HGSOC.18 A study
based on The Cancer Genome Atlas (TCGA) data identified 15
patients of 316 with TP53 wild-type HGSC.19 This finding was
associated with poor prognosis and chemoresistance, possibly
explaining the fact that our patient’s disease was refractory to first-
line platinum-based therapy. A post hoc pathological review of the
TCGA data suggests that p53 wild-type tumors may be misclassi-
fied as HGSOC and could correspond to other disease entities.20
In our case, a histological review of the surgical specimen from
May 2013 confirmed the initial diagnosis of HGSOC (Figure 1)
and has been reviewed by two expert pathologists. Finally, it is
important to note that our NGS panel includes only hotspot
mutations and that is possible that a rare TP53 mutation in
a not included region exists.
The benefit of hormonotherapy in ovarian cancer is generally
anecdotal and remains somewhat controversial.20,21 This tumor
expressed both estrogen and progesterone receptors, which
could favor response to hormonotherapy.22,23 Pre-clinical data
demonstrated that ER-positive breast cancer cell lines were also
more sensitive to palbociclib than other breast cancer cell lines.11
In addition, the action of tamoxifen and palbociclib appears to
be synergistic in cell lines sensitive to anti-estrogen therapy and
overcomes resistance in those who have acquired a resistant
phenotype. The combination of an anti-estrogen with palboci-
clib in ER-positive breast cancer reinforces the effect of inhibi-
tion of Rb phosphorylation, diminishes the expression of key
transcription factors as E2F and FOXM1, and increases the
expression of senescence markers.24
Our case demonstrates durable clinical benefit with the
association of palbociclib and letrozole in heavily pretreated,
platinum-refractory ovarian cancer positive for ER/PgR and
harboring bi-allelic CDKN2A loss. Given the rarity of
CDKN2A loss in ovarian cancer, our report supports further
research in this direction for the discovery of reliable predic-
tive biomarkers.
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Materials and methods
The patient provided written informed consent for publication
of this case report, in accordance with institutional policy.
Next-generation sequencing
The sequencing of tumor tissue was done with the IonAmpliseq
Cancer Hotspot Panel v2 (ThermoFisher, cat# 4475346) on an
IonTorrent Proton sequencer. Variant calling was performed
with the TorrentVariantCaller then manually curated. Variants
with allele frequency below 5% or present in normal DNA were
not reported.
Copy number variation analysis
Copy-number variation (CNV) analysis was done on 80ng
genomic DNA isolated from FFPE tumor tissues with the
Affymetrix OncoScan® FFPE Assay Kit according to the man-
ufacturer’s instructions. CEL files from the scanned array
images were imported into the Chromosome Analysis Suite
(ChAS 3.3) software to generate probe set analysis results.
Genomic copy number variations and LOH of regions as
small as 25kb were automatically highlighted by the software
and were further evaluated manually.
P16INK4a immunohistochemical staining
Immunohistochemical staining for p16 was carried out on
4 μm FFPE sections using the CINtec Histology Kit
(Ventana) according to the manufacturer’s instructions.
High grade papillary serous carcinoma
immunohistochemical staining
Stainings were performed on a Ventana benchmark ultra automat
using the following antibodies (estrogen receptor – SP1 pre-
diluted Roche Ventana Tucson, progesterone receptor – 1E2 pre-
diluted Roche Ventana Tucson, PAX8 – BCL12, ABCAM,
Cambridge UK) and the following protocols (estrogen receptor –
buffer CC1 at 96C for 36 minutes, progesterone receptor – buffer
CC1 64 minutes at 96C, PAX8 – diluted 1:20 buffer CC1 48 min-
utes at 96C).
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